Typical response-time courses obtained after different doses and routes of administration (3 and 10 µg i.v., and 10, 50, and 100 µg s.c.). Typical response-time.

Slides:



Advertisements
Similar presentations
PHARMACOKINETIC.
Advertisements

Pharmacokinetics of Drug Absorption
Pharmacokinetics a. route of administration b. absorption and elimination Pharmacodynamics a. dose-effect curve b. therapeutic index c. ligand binding.
Bioavailability of Drugs with Nonlinear Pharmacokinetics (PK) Can be Approximated by the Ratio of Doses that Provide Equal Areas under the Concentration-Time.
Fundamentals of Drug Action
Pharmacokinetics of Drug Absorption Prepared by: KAZI RASHIDUL AZAM.
Intravenous Infusion Previous rates of administration were instantaneous IV bolus and first order absorption. As a rate (mg/hr) a first order rate constantly.
CHAPTER 7 ABSORPTION KINETICS.
Pharmacokinetics of Drug Absorption Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
Clinical Pharmacokinetic Equations and Calculations
Study Aids Anki Flash cards – Content that you need to know for the tests. MS Excel sheet with Calculations.
415 PHT Plasma Level – Time Curve
Practice Problems Biopharmaceutics-I.
Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:
Drug Response Relationships
Volume 9, Issue 8, Pages (August 2017)
Routes of Administration
Plasma drug concentration-time profiles after IV infusion
Applications of Pharmacokinetics
The 3-compartment pharmacokinetic model
INTRODUCTION The oral route of drugs administration is the most important method of administering drugs for systemic effects.
Quantitative Pharmacokinetics
Absorption, Distribution, Metabolism and Elimination: Part I
Pharmacokinetic–Pharmacodynamic Modeling of Opioids
administration (single dose, 5 mg) in six healthy male volunteers.
1 Concentration-time curve
GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers  J.F. McLeod, J.M. Leempoels, S.X.
Geometric mean concentration-time profiles of (A) racemic BUP, R-BUP, and S-BUP; (B) racemic OHBUP, RR-OHBUP, and SS-OHBUP; (C) racemic ERY, SR-ERYHBUP,
The additive model assumes unspecific effects of equal size in both the placebo and drug arm or groups of studies or experiments. The additive model assumes.
Itraconazole tissue and fluid concentrations in humans as multiples of the maximal or simultaneously measured concentration in plasma (μg/ml) after systemic.
Observed (symbols) and model predicted (lines) dopamine time courses in rats following D-amphetamine administration. Observed (symbols) and model predicted.
Voriconazole tissue and fluid concentrations in humans as multiples of the maximal or simultaneously measured concentration in plasma (μg/ml) after systemic.
Concentrations of abemaciclib in plasma and cerebrospinal fluid (CSF).
Microbial contribution to drug metabolism.
Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.
Nanoemulsions as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats  Sateesh Khandavilli, Ramesh Panchagnula 
Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.
Chronic effect of 28-day oral administration of vehicle (n = 6–10/group) or aprocitentan 1, 10, and 100 mg/kg per day (n = 6–9/group) on mean arterial.
Effect of 11-day oral administration of vehicle (n = 4) or 6-day oral administration of enalapril 10 mg/kg per day (n = 19), followed by 5-day oral administration.
Three drug delivery strategies for crossing the blood-brain barrier.
Dan-dan Tian1, 2 et al. Acta Pharmacol Sin 2015; 36: 627–643;
F. Estelle R. Simons, MD, FRCPCa, Xiaochen Gu, PhDb, Keith J
Effects of gemfibrozil on the exposure (area under the plasma drug concentration-time curve) to different CYP2C8 substrate drugs. Effects of gemfibrozil.
Mean (SD) AMG 557 serum concentration–time profiles following single-ascending dose (SAD) (A) and multiple-ascending dose (MAD) (B) administration AMG.
(A) Plasma renin activity in Wistar rats, SHRs, and DOCA-salt rats, n = 8 to 9/group; data are presented as mean ± S.E.M. Dose-response relationship on.
Drug levels during the course of a dosing interval.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Schematic illustration of exposure-driven response models (upper row) and biophase-driven response (bottom row). Schematic illustration of exposure-driven.
Observed (symbols) and predicted (solid lines, eq
Chen Cheng1 et al. Acta Pharmacol Sin 2013; 34: 1337–1348;
Dose-normalized plasma concentration-time curves of a mAb following subcutaneous (SC) and intravenous (IV) administration to cynomolgus monkeys (mean ±
Mean plasma concentrations of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis (duration depicted by box.
Intracerebroventricular (ICV) insulin infusion increases TG secretion.
Fig. 5 In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig. In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig.
A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously  Shilpa H. Desai, BS, MD, Akhil Chouksey, MD, John Poll, RN, Melvin Berger,
Multivariable analysis of Clinical Disease Activity Index (CDAI) over time modelled with a cubic effect of time and adjusted for age, gender, disease duration,
Enrollment, outcomes, and pharmacokinetics.
(Left) Observed (symbols) and model-predicted (lines) response (tail flick) vs. time of drug X after different doses given by the intravenous (red) and.
Unbound drug concentrations in plasma (dotted) and brain ISF (solid, calculated from recovery and dialysate concentration) following repeated subcutaneous.
(Top) Observed (symbols) and model-predicted (lines) response-time data for latanoprost at the 0.1, 1.0, and 10 µg dose levels in the cat eye. (Top) Observed.
A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.
A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects by Naoki Uchida, Takehiko Sambe, Koichiro.
Activation and desensitization of the α7 nAChRs.
Fig. 3 Double-resonance solid-state NMR data of ceria nanoparticles.
Mean serum concentration time profiles of anifrolumab following subcutaneous and intravenous administration of anifrolumab.a aData below the limits of.
Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.
Average trastuzumab serum concentrations in female minipigs following single subcutaneous administration of trastuzumab in formulations without and with.
Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.
(Left) Observed (symbols) and predicted (lines) response (bacterial count, CFU) vs. time after administration of 1.5, 2, 4, and 6 µg of a new antibiotic.
Pharmacodynamic and pharmacokinetic evaluation of EXE-RM-LNC in a high-fat diet (HFD)-induced obese/diabetic mouse model following acute treatment. Pharmacodynamic.
Presentation transcript:

Typical response-time courses obtained after different doses and routes of administration (3 and 10 µg i.v., and 10, 50, and 100 µg s.c.). Typical response-time courses obtained after different doses and routes of administration (3 and 10 µg i.v., and 10, 50, and 100 µg s.c.). Letters denote the following: A, baseline; B, time delay between expected peak concentration in plasma and observed peak response; C, concave onset of action; D, peak shifts in the response-time courses with increasing doses; E, saturation at top doses; and F, decline of response is slower (absorption rate–limited elimination from biophase) after subcutaneous dosingcompared with intravenously at equal doses. The black bar in the lower-left corner shows the expected peak time of drug in plasma after an intravenous dose or oral solution. See also Table 1 for a suggestion of parameterizations. IV, intraveonous; SC, subcutaneous. Johan Gabrielsson et al. Pharmacol Rev 2019;71:89-122 Copyright © 2018 by The Author(s)‏